EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations
Standard
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. / Nast, A; Smith, C; Spuls, P I; Avila Valle, G; Bata-Csörgö, Z; Boonen, H; De Jong, E; Garcia-Doval, I; Gisondi, P; Kaur-Knudsen, D; Mahil, S; Mälkönen, T; Maul, J T; Mburu, S; Mrowietz, U; Reich, K; Remenyik, E; Rønholt, K M; Sator, P G; Schmitt-Egenolf, M; Sikora, M; Strömer, K; Sundnes, O; Trigos, D; Van Der Kraaij, G; Yawalkar, N; Dressler, C.
In: J EUR ACAD DERMATOL, Vol. 34, No. 11, 11.2020, p. 2461-2498.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations
AU - Nast, A
AU - Smith, C
AU - Spuls, P I
AU - Avila Valle, G
AU - Bata-Csörgö, Z
AU - Boonen, H
AU - De Jong, E
AU - Garcia-Doval, I
AU - Gisondi, P
AU - Kaur-Knudsen, D
AU - Mahil, S
AU - Mälkönen, T
AU - Maul, J T
AU - Mburu, S
AU - Mrowietz, U
AU - Reich, K
AU - Remenyik, E
AU - Rønholt, K M
AU - Sator, P G
AU - Schmitt-Egenolf, M
AU - Sikora, M
AU - Strömer, K
AU - Sundnes, O
AU - Trigos, D
AU - Van Der Kraaij, G
AU - Yawalkar, N
AU - Dressler, C
N1 - © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2020/11
Y1 - 2020/11
N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
U2 - 10.1111/jdv.16915
DO - 10.1111/jdv.16915
M3 - Other (editorial matter etc.)
C2 - 33349983
VL - 34
SP - 2461
EP - 2498
JO - J EUR ACAD DERMATOL
JF - J EUR ACAD DERMATOL
SN - 0926-9959
IS - 11
ER -